First Time Loading...

Shenzhen Kangtai Biological Products Co Ltd
SZSE:300601

Watchlist Manager
Shenzhen Kangtai Biological Products Co Ltd Logo
Shenzhen Kangtai Biological Products Co Ltd
SZSE:300601
Watchlist
Price: 21.21 CNY -0.19% Market Closed
Updated: May 7, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Income Statement

3.1B
-0.1%
Revenue
Growth Rates:
1 Year
-20%
3 Years
+55%
5 Years
+64%
7 Years
+565%
10 Years
-
292.2m
+95%
Operating Income
Growth Rates:
1 Year
-20%
3 Years
-54%
5 Years
-43%
7 Years
+239%
10 Years
-
361.2m
+40%
Net Income
Growth Rates:
1 Year
-16%
3 Years
-37%
5 Years
-17%
7 Years
+321%
10 Years
-

Earnings Waterfall
Shenzhen Kangtai Biological Products Co Ltd

Revenue
3.1B CNY
Cost of Revenue
-531m CNY
Gross Profit
2.5B CNY
Operating Expenses
-2.2B CNY
Operating Income
292.2m CNY
Other Expenses
69m CNY
Net Income
361.2m CNY

Income Statement
Shenzhen Kangtai Biological Products Co Ltd

Rotate your device to view
Income Statement
Currency: CNY
Jun-2016 Sep-2016 Dec-2016 Mar-2017 Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023
Revenue
Revenue
436
N/A
460
+5%
552
+20%
552
0%
816
+48%
1 006
+23%
1 161
+15%
1 419
+22%
1 756
+24%
1 867
+6%
2 017
+8%
1 955
-3%
1 761
-10%
1 911
+9%
1 943
+2%
1 779
-8%
2 006
+13%
1 969
-2%
2 261
+15%
2 361
+4%
2 443
+3%
3 218
+32%
3 652
+13%
4 247
+16%
4 428
+4%
3 840
-13%
3 157
-18%
3 034
-4%
3 060
+1%
3 057
0%
Gross Profit
Cost of Revenue
(147)
(134)
(119)
(106)
(119)
(130)
(153)
(161)
(191)
(196)
(184)
(179)
(162)
(163)
(165)
(164)
(168)
(163)
(231)
(268)
(345)
(513)
(1 136)
(1 091)
(1 089)
(974)
(774)
(503)
(507)
(531)
Gross Profit
290
N/A
326
+13%
433
+33%
445
+3%
697
+57%
877
+26%
1 008
+15%
1 257
+25%
1 565
+24%
1 671
+7%
1 833
+10%
1 777
-3%
1 599
-10%
1 748
+9%
1 779
+2%
1 616
-9%
1 838
+14%
1 807
-2%
2 031
+12%
2 093
+3%
2 098
+0%
2 706
+29%
2 516
-7%
3 156
+25%
3 339
+6%
2 865
-14%
2 384
-17%
2 531
+6%
2 553
+1%
2 526
-1%
Operating Income
Operating Expenses
(207)
(240)
(346)
(404)
(579)
(677)
(766)
(882)
(1 049)
(1 154)
(1 340)
(1 292)
(1 140)
(1 189)
(1 120)
(1 074)
(1 189)
(1 178)
(1 318)
(1 388)
(1 343)
(1 336)
(1 138)
(1 472)
(2 239)
(2 500)
(2 108)
(2 953)
(2 403)
(2 234)
Selling, General & Administrative
(174)
(207)
(290)
(370)
(553)
(670)
(701)
(916)
(1 079)
(1 142)
(1 149)
(1 140)
(951)
(983)
(933)
(916)
(1 023)
(1 014)
(1 052)
(1 114)
(1 078)
(1 009)
(819)
(1 025)
(1 148)
(1 284)
(1 352)
(1 327)
(1 333)
(1 313)
Research & Development
0
(24)
(40)
0
0
(27)
(85)
(28)
0
(51)
(167)
(156)
(201)
(219)
(189)
(206)
(212)
(215)
(243)
(299)
(307)
(347)
(324)
(384)
(569)
(713)
(745)
(791)
(707)
(579)
Depreciation & Amortization
0
(9)
(16)
0
0
0
(21)
0
0
0
(38)
0
0
0
(45)
0
0
0
(51)
0
0
0
(61)
0
0
0
(84)
0
0
0
Other Operating Expenses
(33)
0
(0)
(34)
(26)
20
40
61
31
38
14
5
12
13
46
49
46
51
28
25
43
20
65
(63)
(521)
(503)
74
(836)
(364)
(341)
Operating Income
83
N/A
86
+4%
87
+1%
42
-52%
119
+186%
200
+68%
242
+21%
375
+55%
516
+38%
517
+0%
493
-5%
485
-2%
460
-5%
560
+22%
658
+18%
542
-18%
649
+20%
628
-3%
712
+13%
705
-1%
756
+7%
1 370
+81%
1 378
+1%
1 684
+22%
1 100
-35%
365
-67%
276
-24%
(422)
N/A
150
N/A
292
+95%
Pre-Tax Income
Interest Income Expense
(0)
(1)
(1)
(2)
(2)
(1)
0
(1)
(1)
(2)
(11)
(12)
(12)
(11)
2
4
21
43
66
95
103
92
90
66
52
43
26
22
10
7
Non-Reccuring Items
(1)
0
0
0
(6)
(6)
0
(6)
0
0
(5)
0
(1)
(1)
(2)
0
(0)
0
(8)
(0)
(0)
0
(16)
0
0
0
(621)
0
1
(1)
Gain/Loss on Disposition of Assets
(1)
(1)
(0)
0
(1)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Other Income
11
13
14
20
4
3
(4)
(33)
(22)
(19)
13
5
4
0
6
4
(3)
(5)
3
(1)
(8)
(8)
(12)
(18)
(6)
(11)
(19)
(18)
(20)
(15)
Pre-Tax Income
93
N/A
98
+5%
99
+1%
59
-41%
113
+91%
193
+72%
238
+23%
334
+41%
494
+48%
497
+1%
489
-2%
477
-2%
451
-6%
548
+22%
663
+21%
549
-17%
667
+21%
667
+0%
772
+16%
799
+3%
851
+6%
1 455
+71%
1 439
-1%
1 731
+20%
1 147
-34%
398
-65%
(338)
N/A
(418)
-24%
141
N/A
283
+101%
Net Income
Tax Provision
(11)
(12)
(13)
(7)
(12)
(25)
(23)
(38)
(63)
(63)
(53)
(52)
(43)
(58)
(89)
(72)
(91)
(90)
(93)
(97)
(95)
(173)
(176)
(220)
(100)
33
206
218
116
78
Income from Continuing Operations
82
86
86
52
101
168
215
296
431
435
436
426
408
490
575
477
576
577
679
702
756
1 282
1 263
1 512
1 047
430
(133)
(201)
257
361
Net Income (Common)
82
N/A
86
+5%
86
+1%
52
-40%
101
+93%
168
+67%
215
+28%
296
+38%
431
+45%
435
+1%
436
+0%
426
-2%
408
-4%
490
+20%
575
+17%
477
-17%
576
+21%
577
+0%
679
+18%
702
+3%
756
+8%
1 282
+70%
1 263
-1%
1 512
+20%
1 047
-31%
430
-59%
(133)
N/A
(201)
-51%
257
N/A
361
+40%
EPS (Diluted)
0.15
N/A
0.15
N/A
0.16
+7%
0.09
-44%
0.16
+78%
0.27
+69%
0.35
+30%
0.47
+34%
0.69
+47%
0.69
N/A
0.7
+1%
0.68
-3%
0.64
-6%
0.77
+20%
0.9
+17%
0.73
-19%
0.87
+19%
0.86
-1%
1.01
+17%
1.01
N/A
0.68
-33%
1.13
+66%
1.14
+1%
1.35
+18%
0.94
-30%
1.59
+69%
-0.12
N/A
-0.17
-42%
0.23
N/A
0.32
+39%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 135,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.